Startling results with new breast cancer therapy

Results from a major drug trial are set to change the way clinicians manage postmenopausal women with advanced oestrogen-positive, HER2-negative breast cancer.

In the phase 3  PALOMA-2 trial, palbociclib, when used in conjunction with letrozole, almost doubled progression-free survival to 25 months, compared with 14 months for letrozole plus placebo.

Palbociclib (Ibrance) is an oral treatment which